Alzamend Neuro(ALZN) - 2025 Q4 - Annual Results

Form 8-K Filing Information This section details the registrant's official information, securities listing, and emerging growth company status for the Form 8-K filing Registrant Details This section provides the official details of Alzamend Neuro, Inc. as the registrant for this Form 8-K filing, including its incorporation state, commission file number, and principal executive offices - Registrant: Alzamend Neuro, Inc.[2] - State of Incorporation: Delaware[2] - Commission File Number: 001-40483[2] Securities Information The company's common stock is listed on The Nasdaq Capital Market under the symbol ALZN Securities Registered Pursuant to Section 12(b) of the Act | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :-------------------------- | :---------------- | :---------------------------------------- | | Common Stock, $0.0001 par value | ALZN | The Nasdaq Capital Market | Emerging Growth Company Status Alzamend Neuro, Inc. identifies itself as an 'emerging growth company' but has not elected to use the extended transition period for complying with new or revised financial accounting standards - The registrant is an 'emerging growth company'[4] - The registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards[4] Item 2.02 Results of Operations and Financial Condition This section covers the announcement of financial results, associated legal disclaimers, and forward-looking statements Financial Results Announcement Alzamend Neuro, Inc. announced its audited financial results for the year ended April 30, 2025, via a press release issued on July 23, 2025, which is attached as Exhibit 99.1 to this Form 8-K - Alzamend Neuro, Inc. issued a press release on July 23, 2025, announcing audited financial results for the year ended April 30, 2025[5] - The press release is attached as Exhibit 99.1 and incorporated by reference[5] Legal Disclaimers The information provided in Item 2.02 and Exhibit 99.1 is not considered 'filed' for certain sections of the Securities Exchange Act of 1934 or the Securities Act of 1933, limiting its liability and incorporation by reference into other SEC filings unless explicitly stated - Information in Item 2.02 and Exhibit 99.1 is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 or Sections 11 and 12(a)(2) of the Securities Act of 1933[6] - This information shall not be incorporated by reference into other SEC filings unless expressly set forth by specific reference[6] Forward-Looking Statements The report includes forward-looking statements, which are subject to inherent uncertainties and risks that could cause actual results to differ materially from expectations, and investors are cautioned against undue reliance on them - This Current Report on Form 8-K and its exhibits may contain 'forward-looking statements' as defined by the Private Securities Litigation Reform Act of 1995[7] - These statements involve risks and uncertainties that could cause actual results to differ materially from anticipated outcomes[7] - Investors are cautioned not to rely unduly on forward-looking statements[7] Additional Information and Exhibits This section directs readers to where they can find additional SEC filings and lists all exhibits furnished with the Form 8-K Where to Find Additional Information Investors can access additional documents filed by Alzamend Neuro, Inc. with the Securities and Exchange Commission (SEC) free of charge through the SEC's website or at its public reference room - Documents filed with the SEC are available free of charge at **www.sec.gov**[9](index=9&type=chunk) - Reports and other information can also be read and copied at the SEC public reference room in Washington D.C.[9] Item 9.01 Financial Statements And Exhibits This section lists the exhibits furnished with the Form 8-K, including the press release announcing financial results and XBRL-related documents for electronic filing Exhibits Furnished with Form 8-K | Exhibit No. | Description | | :---------- | :------------------------------------------------------------------------------------------------------ | | 99.1 | Press Release issued on July 23, 2025 | | 101 | Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language) | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101) | Signature This section certifies the report's submission on behalf of Alzamend Neuro, Inc. by its Chief Financial Officer Report Certification The report is duly signed on behalf of Alzamend Neuro, Inc. by its Chief Financial Officer, David J. Katzoff, certifying compliance with the Securities Exchange Act of 1934 - The report was signed on July 23, 2025[14] - Signed by David J. Katzoff, Chief Financial Officer of Alzamend Neuro, Inc.[14]